Health & Biotech: Mesoblast still not in the black, but theyre less in the red than last year – Stockhead

Stem cell biotech Mesoblast (ASX:MSB) has slashed its quarterly losses as it cut deals in Japan and China, and stepped up from R&D to partnering on its current treatments.

The September quarter loss was more than three times lower than in the same period last year, hitting $US5.5m ($8.1m) from $US19.5m ($28.8m). Revenue was up 46 per cent to $17m.

Mesoblast, which makes cellular medicines for remestemcel-L for conditions such as acute graft versus host disease (GVHD), advanced heart failure and chronic low back pain due to degenerative disc disease, recognised the change came from two areas.

The company struck a $US150m deal with German pain management company Grnenthal in September which paid out $US15m that month, for a partnership to develop and commercialise an allogeneic stem cell therapy used to treat chronic low back caused by degenerative disc disease.

Royalty revenue on sales of TEMCELL in Japan, for GVHD rose to $US1.9m.

The other side of the story is that R&D costs have plunged by 33 per cent to $12.2m as the costs for phase three clinical trials for advanced heart failure drug Revascor and low back pain drug MPC-06-ID begin to wind down.

The last patient visit for a 24-month follow up in the MPC-06-ID trial will be before June next year, and full primary endpoints or the key outcomes a trial wants to deliver are expected by the end of 2019.

Mesoblast is showing the way for small caps like Cynata (ASX:CYN) which are tackling similar diseases using cellular treatments.

Proteomics (ASX:PIQ) is spending $1.25m to help build its Western Australian Proteomics Facility to do research on biological markers affecting medicine, agriculture, the environment and marine world. Bioplatforms Australia, and the University of Western Australia are co-investors in the $4.4m site.

Bio-Gene (ASX:BGT) has won a fight with AusIndustry over a tax refund, getting $350,000 the organisation had deemed out of the refund scope. Its also pleased with the $465,293 refund it got for fiscal 2019 wouldnt we all be?

Memphasys (ASX:MEM) is now selling its Felix sperm separator to investors, after it launched earlier this month. The device, initially tested on thoroughbred horses, separates bad (human) sperm from good. Memphasys is playing up the human fertility rates in decline card, and putting fear into men that their lack of babies is, in fact, their fault.

The rest is here:
Health & Biotech: Mesoblast still not in the black, but theyre less in the red than last year - Stockhead

Related Post